Search Hotels in Sausalito

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Topics Economy

Amgen Expands US Manufacturing Network Amid New Tariff Policy

September 26, 2025

Via Benzinga

Topics Government World Trade

Your AstraZeneca Medicine Could Be Cheaper As Much As 70%

September 26, 2025

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent...

Via Benzinga

Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs

September 26, 2025

To gain an edge, this is what you need to know today.

Via Benzinga

Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies

September 26, 2025

Stock Market Soars: Inflation Data Aligns with Expectations, Igniting Hopes for Continued Fed Easing

Topics Government

September 26, 2025

New York, NY – September 26, 2025 – U.S. stock market futures, including the Dow, S&P 500, and Nasdaq, registered notable advances today, signaling a robust open after the release of August's inflation...

All three of these stocks pay fast-growing dividends.

Topics Bonds Economy Government

3 Strong-Buy Dividend Growth Stocks

September 26, 2025

Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst

September 26, 2025

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly...

Via Benzinga

Topics Government World Trade

Eli Lilly Terminates Study Of Bimagrumab In Obesity

September 25, 2025

Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas

September 23, 2025

Eli Lilly secured FDA approval for breast cancer drug Inluriyo and EU clearance for Alzheimer's therapy Kisunla following strong Phase 3 data.

FDA Approves Eli Lilly's Drug For Advanced Breast Cancer

September 26, 2025

Via Benzinga

Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?

September 26, 2025

The pharmaceutical giant is again plunging headfirst into weight-loss drug development.

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet

Topics Intellectual Property

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.

September 26, 2025

Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.

The European Commission cleared its Alzheimer’s drug Kisunla, adding another country to the company’s list where the once-monthly therapy is approved.

Why Is Eli Lilly’s Stock Rising Premarket?

September 26, 2025

Topics Government World Trade

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

September 25, 2025

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was...

Topics Government

Eli Lilly (LLY) Stock Trades Down, Here Is Why

September 25, 2025

Via StockStory

Topics Artificial Intelligence

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?

September 25, 2025

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it...

Via Benzinga

AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection

September 25, 2025

In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July...

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Topics Artificial Intelligence

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

September 25, 2025

Via Benzinga

Does This Acquisition Make Pfizer Stock a Great Buy?

September 25, 2025

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

The latest data from the company's oral weight loss drug is bullish for the stock.

Topics Death Intellectual Property

1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today

September 25, 2025

Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.

Topics Economy

September 25, 2025

Investors once speculated that Pfizer might consider acquiring Viking.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

3 Small-Cap Stocks We Keep Off Our Radar

September 25, 2025

Via StockStory

Healthcare Sector Grapples with 5% Slump in 2025: A Deep Dive into Market Underperformance

September 24, 2025

The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year...

Once up and running, it and other projects should make the company's supply chain stronger.

Topics Artificial Intelligence ETFs Economy

Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?

September 24, 2025

Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines.

Topics Artificial Intelligence Economy

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO

September 24, 2025

Via Benzinga

Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset

September 24, 2025

Via Benzinga

Topics ETFs

STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy

September 23, 2025

STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights...